What ARA-290 is
ARA-290, later called cibinetide, is an 11-amino-acid peptide derived from a surface region of erythropoietin and designed to study tissue-protective signaling without stimulating red-blood-cell production. It is not epoetin, and it has no FDA-approved product or indication.
Human findings are small and endpoint-specific
A 22-person randomized pilot in sarcoidosis-associated small-fiber neuropathy evaluated four weeks of treatment and reported improvement in a symptom measure.[1] A 64-person phase 2b trial found an increase in corneal nerve-fiber area at one tested dose, a surrogate measure; the placebo-corrected pain result in the relevant subgroup was not statistically significant.[2]
These results are hypothesis-generating and do not establish cibinetide for neuropathic pain, nerve repair, metabolic control, eye disease, recovery, or general anti-inflammatory use.
Safety and evidence limits
Short monitored trials provide some human tolerability data but are too small and brief to define uncommon, delayed, pregnancy, interaction, cancer, or long-term immune risks. Related erythropoietin drug warnings cannot simply be assigned to cibinetide, but the absence of a cibinetide label also means no regulator-reviewed adverse-reaction table or monitoring standard exists.
Designation is not approval
FDA orphan designation records show development interest for sarcoidosis-related indications, not marketing approval.[3] ARA-290/cibinetide remains investigational in the United States. Teloryx does not publish a dose, cycle, or reconstitution recipe outside trial context.